These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 21296524

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist.
    Patel V, Case R.
    J Investig Med High Impact Case Rep; 2020; 8():2324709620944709. PubMed ID: 32720820
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R, Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma.
    J Clin Oncol; 2003 Dec 01; 21(23):4402-6. PubMed ID: 14581437
    [Abstract] [Full Text] [Related]

  • 6. Transfusion medicine illustrated: An unusual case of near-fatal hemolytic anemia treated with erythrocytapheresis and therapeutic plasma exchange.
    Dasararaju R, Adamski J.
    Transfusion; 2015 Mar 01; 55(3):475. PubMed ID: 25759128
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Fast remission of acute kidney failure after rasburicase use in tumor lysis syndrome].
    Viedma G, Borrego FJ, Pérez del Barrio P, de Santi C.
    Nefrologia; 2005 Mar 01; 25(5):572-3. PubMed ID: 16392310
    [No Abstract] [Full Text] [Related]

  • 11. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN, Shanholtz CB, Thompson JL.
    Ann Pharmacother; 2010 Oct 01; 44(10):1529-37. PubMed ID: 20841516
    [Abstract] [Full Text] [Related]

  • 12. Tumor lysis syndrome: pathogenesis and management.
    Jones DP, Mahmoud H, Chesney RW.
    Pediatr Nephrol; 1995 Apr 01; 9(2):206-12. PubMed ID: 7794722
    [Abstract] [Full Text] [Related]

  • 13. Severe hyperphosphatemia associated with tumor lysis in a patient with T-cell leukemia.
    Saleh RA, Graham-Pole J, Cumming WA.
    Pediatr Emerg Care; 1989 Dec 01; 5(4):231-3. PubMed ID: 2602196
    [Abstract] [Full Text] [Related]

  • 14. Renal tubular damage in rasburicase: risks of alkalinisation.
    van den Berg H, Reintsema AM.
    Ann Oncol; 2004 Jan 01; 15(1):175-6. PubMed ID: 14679140
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Rasburicase (Fasturtec)].
    Vogt B, Gugger M, Frey FJ.
    Ther Umsch; 2004 Sep 01; 61(9):579-82. PubMed ID: 15493120
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Cheng FM, Tien JZ, Chen TT, Yeh SP, Lin CC.
    Ann Hematol; 2020 Sep 01; 99(9):2193-2195. PubMed ID: 32621180
    [No Abstract] [Full Text] [Related]

  • 20. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
    Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M.
    Pharmacotherapy; 2006 Feb 01; 26(2):242-7. PubMed ID: 16466328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.